Core Insights - The merger between Dr Ashleys Limited and Impact BioMedical Inc. aims to enhance market reach for innovative pharmaceutical patents, creating a new entity to be traded on the NYSE American under the name "Dr Ashleys Limited" [1][4] - This strategic move highlights the increasing significance of innovation and collaboration within the biomedical industry, leveraging Dr Ashleys' global presence and financial resources to expedite the commercialization of Impact BioMedical's patents [1][2] Company Overview - Dr Ashleys Limited is a global pharmaceutical company focused on developing and manufacturing specialized active pharmaceutical ingredients (APIs) and orphan drugs for rare diseases, addressing critical health issues such as malaria, cancer, and COVID-19 [7][8] - Impact BioMedical Inc. specializes in innovative health solutions, holding a portfolio of over 90 patents aimed at tackling significant health challenges, including infectious diseases [9] Transaction Details - The merger will involve a subsidiary of Dr Ashleys merging with Impact BioMedical, with the latter being the surviving entity, and both companies will become wholly-owned subsidiaries of the newly formed PubCo [3][4] - The management team of Dr Ashleys will operate the new entity, with a new Board of Directors to be established [3] Leadership Statements - Dr. Kanans Visvanats, Director of Dr Ashleys, emphasized that the merger is a milestone in delivering innovative treatments globally, integrating Impact BioMedical's intellectual property into their R&D efforts [2] - Frank D. Heuszel, CEO of Impact BioMedical, expressed enthusiasm about the merger, highlighting the resources and infrastructure that Dr Ashleys can provide to bring their innovations to market [2]